Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*”Architects”: Geriatrics, Gerontology, Geroscience, Longevity, Healthspan & Aging
CohBar, Inc. (NASDAQ: CWBR)

Organization & Developments: CohBar

Parents

2019: Avoid CohBar: Red Flags And An Exorbitant Valuation_seekingalpha.com
2019: CohBar Inc. And CB4211 In NASH: What's The Story?_seekingalpha.com
2021: The company’s lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity.
2021: To date, the company has discovered more than 100 mitochondrial derived peptides and invented over 1,000 analogs.
2023: CohBar Shares Slide to New Depths on Plans to Liquidate
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases.
In addition, CohBar has four preclinical programs.
Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body.